
|Podcasts|January 21, 2022
Key Considerations in Aseptic Fill Finish CMO Facilities
Author(s)Samsung Biologics
Fill finish (sterile filtration) operations are critical and often the only means to produce sterile liquid biopharmaceuticals as other means of sterilization will degrade the product(s). This complex packaging process has become more regulated and controlled in an effort to reduce the risks of contamination (with the greatest risk potential coming from cleanroom operators). This episode reviews current market trends and provides some characteristics expected of a top notch Fill Finish CMO, like Samsung Biologics in Incheon, South Korea.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Insuring Novel Biologic Development Against Geopolitical Developments: Part Three of Three with Abzena
2
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
3
Building Robust Biomanufacturing Networks for the Next Wave of Therapies
4
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
5




